Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer

详细信息    查看全文

• 作者：Insiya B. Poonawalla ; PhD^aAuthor Vitae ; Linda B. Piller ; MD ; MPH^aAuthor Vitae ; David R. Lairson ; PhD^bAuthor Vitae ; Wenyaw Chan ; PhD^cAuthor Vitae ; Xianglin L. Du ; MB ; MS ; PhD^a ; ^{Xianglin.L.Du@uth.tmc.edu" class="auth_mail" title="E-mail the corresponding author}Author Vitae
• 刊名：Women's Health Issues
• 出版年：2016
• 出版时间：September-October 2016
• 年：2016
• 卷：26
• 期：5
• 页码：574-583
• 全文大小：519 K

文摘

To evaluate the risk of thromboembolic and pulmonary toxicities associated with hematopoietic growth factor (HGF) use (i.e., erythropoietin-stimulating agent [ESA] and/or colony-stimulating factor [CSF]) in a community-dwelling cohort of elderly patients with advanced ovarian cancer.

Methods

We studied 8,188 women, 65 years and older from the Surveillance, Epidemiology and End Results-Medicare linked database, diagnosed from January 1, 2000 to December 31, 2009. Patients were categorized into five groups: no chemotherapy and no ESA/CSF (n = 2,616), chemotherapy but no ESA/CSF (n = 1,854), ESA only (n = 1,313), CSF only (n = 743), and ESA + CSF (n = 1,662). We reported the cumulative incidence of toxicities for 2, 6, and greater than 6 months, and the incidence density for the overall follow-up. Cox-proportional hazards regression was performed to determine risk of toxicities.

Results

Of the 5,572 patients receiving chemotherapy, 66.7% (n = 3,718) received HGF supportive treatment, 29.8% received ESA + CSF, 23.6% received ESA only, and 13.3% received CSF only. Patients who received chemotherapy and also ESA + CSF had a 14.1% cumulative incidence of thromboembolic event (TEE) at 6 months of follow-up compared with 8.0% in those who received chemotherapy without growth factor and 3.2% in those with neither chemotherapy nor growth factor. Those with chemotherapy who received ESA + CSF had a significantly higher risk of TEE (adjusted hazard ratio, 1.22; 95% confidence interval, 1.01–1.47) as compared with patients with chemotherapy and no ESA/CSF, although patients aged 85 years and older may experience up to a five-fold increased risk. The risk of pulmonary toxicities did not significantly differ by HGF use.

Conclusions

An increased risk of TEEs was observed in elderly patients with ovarian cancer who received ESA + CSF. The risk–benefit ratio for administering HGF should be carefully evaluated, especially among those 85 years and older.